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doi:10.1016/j.jmii.2011.01.030Background: In Taiwan, liver transplantation is a common treatment of end-stage liver
diseases. Infection has a negative impact on the survival of these patients and their grafts.
We evaluated the timing and frequency of infections, and the risk factors associated with
infection and mortality in liver transplant recipients from Taiwan.
Methods: This retrospective study enrolled all adult patients who underwent orthotopic liver
transplantation from January 2004 to November 2008 at a tertiary hospital in Taiwan.
Results: Sixty-eight patients were enrolled (male/female Z 46/22) and average age was 51.3
years. Bacterial infection (26/68, 38.2%) was the most common infectious disease, with a rate
of 0.3/1,000 person-days in the perioperative period, 0.27/1,000 person-days in the early
operative period, and 0.38/1,000 person-days in the late-operative period. Operation-related
complications increased the risk of bacterial infection. Biliary stricture was the most common
operation-related complication, and this was associated with biliary tract infection
(p < 0.001). The average time from first stent placement for biliary stricture by endoscopic
retrograde cholangiography to biliary tract infection was 34.5 days. The overall mortality rate
was 11.7%, and the mortality rate was 14% for patients with infections.
Conclusions: Bacterial infection was the most common type of infection in liver transplant
recipients. Surgery-related complication, especially biliary tract stricture was risk factor for
infection. We suggest that the current recommendations about the timing of endoscopic retro-
grade cholangiography intervention be reevaluated.
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The first liver transplantation in Taiwan was performed in
1984. Since then, this procedurehas beenperformedatmany
tertiary medical centers in Taiwan as treatment of patients
with end-stage liver diseases. However, postoperative
infection has a major negative impact on the survival of liver
transplant recipients and their grafts. In the past few
decades, researchers from numerous countries have
described the incidence of infection, timing of infection
onset, and risk factors for infections after liver trans-
plantation.1e9However, suchdataare lacking forTaiwan.We
conducted this study to determine the timing, frequency,
and risk factors for infection in 68 liver transplant recipients
at a teaching hospital in Taiwan.
Materials and methods
Patients and setting
China Medical University Hospital is a 2,000-bed teaching
hospital in Taichung City, central Taiwan. This retrospec-
tive study included all adult patients (nZ 68) who were at
least 18 years of age and who received orthotopic liver
transplantation (OLT) from January 2004 to November
2008. Medical charts were thoroughly reviewed and demo-
graphic data, clinical features, and outcomes were recor-
ded and analyzed.
Diagnostic definitions
All diagnoses were based on the definitions proposed by
Garbino et al.10 An infectious episode was defined as the
association of compatible clinical signs and symptoms,
laboratory tests, and a microbial pathogen recovered from
normally sterile body site, followed by the introduction of
an antimicrobial regimen directed against the microor-
ganism identified. Blood stream infection was defined by
the presence of clinical signs of infection and the presence
of microorganisms in at least one blood culture. Biliary
tract infection (BTI) was defined by the typical clinical
symptoms/signs and a positive culture from the drainage
tube. Peritonitis was defined by the typical clinical symp-
toms/signs and the presence of positive peritoneal fluid
cultures obtained by percutaneous drainage or during
surgery. Soft tissue infection was defined by the isolation of
a pathogen from the infected site, which was compatible
with the signs of infection. Intra-abdominal abscess was
defined by the presence of localized purulent fluid collec-
tion and positive microbiological culture. Pneumonia was
defined by the typical clinical manifestations, laboratory
data (including a positive culture), and a new infiltrate on
chest radiography. Cytomegalovirus (CMV) infection was
defined as the presence of: (1) seroconversion of CMV-
specific IgG and IgM in a previously seronegative patient
(primary infection); (2) four-fold or greater increase in the
CMV IgG antibodies titer (secondary infection or reac-
tivation) or positive serum CMV pp65 antigen; or (3) positive
serum CMV polymerase chain reaction or culture. Fungal
infection was diagnosed if patients had one of the
following: (1) positive blood culture; (2) isolation of fungifrom an abdominal specimen with evidence of peritonitis or
intra-abdominal abscess; or (3) tissue invasion proved by
biopsy. Herpes simplex virus (HSV) infection was diagnosed
based on the typical oral or genital ulcer and positive virus
culture. Herpes zoster was diagnosed based on the char-
acteristic dermatome distribution of skin lesion.
Infection episodes that occurred after transplantation
were classified as: perioperative (onset within 1 month),
early operative (onset within 1e6 months), or late opera-
tive (onset after 6 months). The “successful deployment”
of a stent [by endoscopic retrograde cholangiography
(ERC)] or catheter [by percutaneous transhepatic chol-
angial drainage (PTCD)] was defined as the removal of
a stent or catheter with no recurrence of clinical symp-
toms/signs of biliary tract obstruction based on cholangi-
ography of the patent biliary tract. We defined a patient as
“under treated” if the stent or catheter remained in place,
but the biliary tract obstruction remained. Urgent trans-
plantation was performed for fulminant hepatic failure.
Immunosuppressive therapy and diagnosis of
transplant rejection
For immunosuppression, all transplant recipients received
either cyclosporine- or tacrolimus-based combined regi-
mens [cyclosporine/tacrolimus þ mycophenolate mofetil/
mycophynolate sodium þ methylprednisolone (MTP)/pred-
nisolone] after liver transplantation. A possibly acute
rejection episode was diagnosed based on clinical findings
and biochemical data. A liver biopsy was performed to
confirm rejection. When there was clinical suspicion of
acute rejection, MTP (1 g intravenously everyday) was given
for 3 days, and was then replaced with oral prednisolone,
which was tapered gradually.
Perioperative antimicrobial prophylaxis and
surgical procedure
Cefotaxime (2 g, every 8 hours, intravenous drip) and
ampicillin (1 g, every 6 hours, intravenous drip) were used
as perioperative prophylactic antibiotics. If there were no
signs or symptoms of infection, these agents were dis-
continued after 5 days. No prophylactic medication for
Pneumocystis jirovecii, fungus or virus was given.
Preemptive or targeted treatment strategy for CMV was
adopted after liver transplant in our patients. All patients
received choledochocholedochal anastomosis without T
tube or stent placement.11
Statistical analysis
All results were analyzed using SPSS, Version 12.0 (SPSS
Inc., Chicago, IL, USA). For categorical data, proportions
were compared with the c2 test. Continuous variables were
compared with an independent t test. The Kaplan-Meier
method was used for survival analysis. A p value of 0.05 or
less was considered statistically significant. We used
univariate and multivariable logistic regression models to
assess the independent association of various risk factors
with occurrence of bacterial infection postliver trans-
plantation event. For each potential risk factor, the odds
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Figure 1. Episodes of infection at different periods after
orthotopic liver transplantation.
Infection in liver transplant recipients 305ratio for the occurrence of bacterial infection and the 95%
confidence interval were estimated.
Results
Sixty-eight patients (72 transplants, 4 retransplants) were
included in this study, 68% (46/68) were male, and the
average age was 51.3 years. All patients were followed for
more than 6 months, and 93% were followed for more than
1 year. Sixty-seven patients were CMV seropositive before
OLT. The main reasons for first-time OLT were: chronic
hepatitis C infection (29.4%), chronic hepatitis B infection
(22.0%), and chronic hepatitis B infection with hepatocel-
lular carcinoma (11.7%) (Table 1).
Postoperatively, 38% (26/68) of patients had bacterial
infections (50 episodes), 12% (8/68) had viral infections (8
episodes), and 9% (6/68) had fungal infections (6 episodes).
Among patients with bacterial infections, the onset of
infection varied with time. There were 0.3/1,000 person-
days in the perioperative phase, 0.27/1,000 person-days in
the early operative phase, and 0.38/1,000 person-days in
the late-operative phase (Fig. 1).
Table 2 summarizes the species of pathogens isolated
during the postoperative period. For patients with bacterial
infections (nZ 26), Escherichia coli was the most common
species (17 episodes, 34.0%), followed by Pseudomonas
aeruginosa (13 episodes, 26.0%), and Staphylococcus aureus
(4 episodes, 8.0%). For patients with viral infections
(nZ 8), four patients had HSV-1 infections as oral or labial
lesions, three patients had varicella-zoster virus infection,
and one patient had active CMV infection (which appeared
15 months after liver transplantation). For patients with
invasive fungal infections (n Z 6), two had candidemia
(onset at 21 and 765 days after OLT), two had invasive
pulmonary and cutaneous aspergillosis (onset at 14 and 110
days after OLT), and two had disseminated cryptococcosis
(onset at 200 and 661 days after OLT). MycobacteriumTable 1 Reasons for orthotopic liver transplantation
Number Percentage
Chronic liver disease
HBV 15 22.0
HCV 20 29.4
HBV þ HCV 2 2.94
HBV þ HCC 8 11.7
HCV þ HCC 4 5.88
HBV þ HCV þ HCC 1 1.47
Alcoholic liver cirrhosis 6 8.82
Primary biliary cirrhosis 1 1.47
Wilson’s disease 1 1.47
Acute liver failure
HBV-related 6 8.82
Others 4 5.88
Total 68 100
HBV Z hepatitis B virus; HCC Z hepatocellular carcinoma;
HCV Z hepatitis C virus.tuberculosis (TB) infection occurred in one patient at 2
years after liver transplantation.
Table 3 shows the anatomical sites of the bacterial
infections. The biliary tract was the most common site (19
episodes, 38.0%), followed by the blood stream (11 episodes,
22.0%), and lower respiratory tract (5 episodes, 10%).
Next, we compared patients with and without bacterial
infections (Table 4). Univariate analysis for the risk factors
of bacterial infection revealed that the average amount of
blood transfusion (which included whole blood, packed
RBCs, and frozen fresh plasma) (14,945 mL vs. 9,329 mL,
p < 0.01), pretransplantation serum bilirubin level,
retransplant, operation complication, and days of ICU stay
were associated with higher rate of bacterial infection.
Multivariate analysis revealed that only operation compli-
cation had the higher risk for bacterial infection, odds ratio
was 16.04 (Table 5).
A total of 16 patients had rejection events after trans-
plantation (biopsy proven in nine patients, seven possible
cases), and all of them were given MTP pulse immunosup-
pressive therapy. Among these 16 patients, there were 13
infection episodes, 2 at 30 days before the rejection event
(4.0/1,000 patient-days), and 11 at 30 days after that
(22.5/1,000 patient-days). A tacrolimus-based regimen was
administered to 48 transplant recipients, and a cyclo-
sporine-based regimen was administered to 20 patients.
The bacterial infection rates were similar in these two
groups (p Z 0.473).
Operation-related complications occurred in 13 recipi-
ents (19.1%), and these included 10 cases of biliary tract
stricture (14.7%), three cases of bile leakage (4.4%), one
case of subphrenic hematoma (1.47%), and one case of
hepatic artery thrombosis (1.47%). Two patients had stric-
ture and bile leakage. Biliary stricture occurred between
Day 9 and Day 453 after OLT (median: 169 days), with 80% of
these strictures occurring in the early and late-operative
phases. BTI occurred in six patients with biliary tract
stricture (60%), and was significantly associated with biliary
tract stricture (p < 0.001).
Endoscopic biliary stricture dilatation and stent place-
ment was performed for all 10 patients with biliary tract
stricture. One of these patients achieved “success”, two
patients had the status of “under treatment”, and seven
patients had “failure” (all of whom received PTCD for stric-
ture dilatation and bile drainage), six of whom subsequently
developed BTI. None of seven patients who received PTCD
achieved “success”, three remained in the status of “under
Table 2 Infectious organisms identified in orthotopic liver transplant recipients
Perioperative period Early operative period Late-operative period
Bacteria 16 14 20
Staphylococcus aureus 1 3 0
Pseudomonas aeruginosa 4 1 8
Escherichia coli 6 1 10
Stenotrophomonas maltophilia 1 2 0
Klebsiella pneumoniae 0 2 0
Citrobacter freundii 0 1 0
Acinetobacter baumannii 2 1 0
Streptococcus constellatus 2 0 0
Streptococcus viridans 0 1 1
Peptostreptococcus micros 0 0 1
Enterococcus fecalis 0 2 0
Mycobacterium tuberculosis 0 0 1
CMV 0 0 1
HSV 2 2 0
VZV 0 1 2
Candidiasis 1 0 1
Aspergillosis 1 1 0
Cryptococcosis 0 0 2
CMV Z cytomegalovirus; HSV Z herpes simplex virus; VZV Z varicella-zoster virus.
306 T.-C. Chen et al.treatment”, two received stent placement at another
hospital, and two died. The time from initial stent placement
by ERC or catheter placement by PTCD for biliary stricture to
BTI was 34.5 days and 33.2 days, respectively.
Sixty-three recipients (92.7%) were followed for more
than 1 year (mean: 24.8 months). The 1-year survival rate
was 88.8%. Eight patients died during the follow-up period,
six patients died within 6 months of transplantation, and
one died at 11 months after transplantation. The mortality
rate was significantly higher for patients with infections
(14% vs. 0%, p < 0.001), and for patients who received
retransplantation (75% vs. 7.8%, p < 0.01). Figure 2 shows
the Kaplan-Meier survival curve of the infected group and
noninfected group.Discussion
Postoperative infection is a well-known problem for liver
transplant recipients.1e5,10 In this study, we found that 29
liver transplant recipients (42.6%) had infectious complica-
tions postoperatively and that 78% of these infections wereTable 3 Anatomical sites of bacterial infection at three differ
ative: onset within 1 mo; early operative: onset within 1e6 mo;
Perioperative
Bacteremia 5
Pneumonia or empyema 3
Urinary tract infection 2
Peritonitis or intra-abdominal abscess 2
Liver abscess 1
Biliary tract infection 3
Cellulites or wound infection 0
Total (%) 16 (32)because of bacteria. During the early and late-operative
periods, recurrent BTI was the most common cause of
bacterial infection (47%), and these infections were associ-
ated with biliary tract stricture.
Similar to prior studies,3,8 we found that bacterial
infections were the most common infectious complications
(38.2%) in patients receiving OLT. Previous studies have
identified several risk factors associated with bacterial
infections after OLT, including duration of surgery, amount
of blood transfusion, and complications during surgery.1,8 In
our patients, surgical complicationsdbut not duration of
surgery and amount of blood transfusiondwere also asso-
ciated with bacterial infections.
There are many risk factors to influence the rate of
bacterial infectionafter liver transplantation.8Comparedwith
previous studies,3,8 our patients had a lower rate of bacterial
infection. This difference may be attributed to two major
factors: different surgicalmethods and lower confirmedacute
rejection episodes. In earlier reports,1,3 choledochoduodenal
anastomosis was associated with a higher infection rate,
possibly because of the disruption of Oddi’s sphincter. All
of our patients received choledochocholedochal anastomosisent periods after orthotopic liver transplantation (perioper-
late operative: onset after 6 mo)
Early operative Late operative Total (%)
3 3 11 (22)
1 1 5 (10)
0 2 4 (8)
1 1 4 (8)
2 1 4 (8)
5 11 19 (38)
2 1 3 (6)
14 (28) 20 (40)
Table 4 Univariate risk factors for bacterial infection in orthotopic liver transplant recipients
Univariate Risk factors With bacterial infection
(n Z 26)
Without bacterial infection
(n Z 42)
p
Age (mean), yr 52.1 50.6 0.54
Gender (male/female) 18/8 28/14 0.82
Pretransplantation laboratory data
White blood cell, /mL 5,249 5,422 0.81
Hemoglobin, g/dL 11.5 10.7 0.13
Platelet, /mL 85,720 62,370 0.06
Bilirubin, total, mg/dL 14.4 7.0 0.007
Serum GPT, IU/L 266.9 77.5 0.06
Creatinine, mg/dL 1.4 1.1 0.37
Prothrombin time, s 24.8 20.4 0.20
Albumin, g/dL 2.6 2.5 0.77
Elective/urgent transplantation 23/3 39/3 0.48
ICU stay, d 8.5 3.8 0.001
Co-morbidity, patient numbers 10 10 0.19
Operation time, hr 15.5 15.4 0.92
Blood transfusion, mL 14,953 9,458 0.005
Immunosuppression regimen (tacrolimus/cyclosporin) 20/6 27/15 0.473
Rejection (yes/no) 22/4 37/5 0.68
Retransplant (yes/no) 4/22 0/42 0.007
Operation complication, patient numbers 11 2 <0.001
GPT Z glutamic pyruvic transaminase.
Infection in liver transplant recipients 307of the bile duct, a procedure that preserves the function of
Oddi’s sphincter anddecreases the rateof ascending infection
from the intestine and resulting bacteremia.1,3 Lower con-
firmed acute rejection episodes in this study reduce the MTP
bolus for rejection treatment. High-dose MTP treatment of
acute rejectionwill increase the infection episodes, as seen in
former studies and this study.10 So, decreased MTP bolus for
acute rejection can reduce the infection episodes in this study
than others. Furthermore, culture was not all done when
infection was suspected. In this study, episode was collected
only when a positive culture result was seen. This under-
estimated the true bacterial infection episodes.
In other previous studies,1e3,10 bacterial infection
occurred most frequently in the perioperative period; by
contrast, we observed no difference in bacterial infection
rates during the perioperative, early operative, and late-
operative periods. This difference could be because of the
occurrence of recurrent BTI, which was more common in the
early and late-operative periods. BTI accounted for 47% of all
episodes of bacterial infection in our early and late-opera-
tive periods (16 episodes), and 14 of these episodes wereTable 5 Multivariate risk factors for bacterial infection in
orthotopic liver transplant recipients
Categories AOR Range p
Operation complication (patient numbers)
No (n Z 55) 1 (reference)
Yes (n Z 13) 16.04 3.42e75.30 <0.0001
ICU stay 0.97 0.87e1.09 0.636
Adjusted age, sex.
ICU Z intensive care unit; AOR Z adjusted odds ratio.related to biliary tract stricture. A previous study observed
biliary complications in 11e29% of patients receiving liver
transplantation,11 with anastomotic stricture the most
common complication.12,13 We observed biliary tract stric-
ture in 14.7% of our patients, similar to that of other studies
of liver transplant recipients (5e17.8%).12,13 A previous study
found that most episodes of biliary tract stricture occurred
after 1 month of transplantation,14 similar to the present
study. Furthermore, our data showed that BTI was highly
correlated to biliary tract stricture (p< 0.0001), and thismay
explain the higher bacterial infection rates in the early and
late-operative periods of our study.
Historically, different surgical methods have been used to
manage anastomotic biliary stricture.15 Before the late 1980s,
surgical intervention was mostly used to correct trans-
plantation-related biliary tract stricture; since then, percu-
taneous transhepatic cholangiography or ERC aremorewidely
used. Currently, percutaneous transhepatic cholangiography
and ERC have a high success rates (88%).16 It is currently rec-
ommended that the biliary stent be replaced every 3
months;16 however, based on our findings, the mean time
between stent placement and BTI was 34.5 days. Thus, we
suggest that ERC be performed more frequently than the
current recommendation to prevent biliary tract restenosis.
On the other hand, the mean time between PTCD catheter
placement to BTI was 33.2 days, so the current recommen-
dation of monthly PTCD revision seems reasonable.17
The incidence of TB in liver transplant recipients varies
significantly, from 0.35% in developed countries to 15% in
endemic areas.18e21 Most cases of TB occur within 12
months of transplantation, and tend to present as pulmo-
nary TB.21 In the present study, only one patient (1.5%)
had hepatic TB, and this was diagnosed 797 days after
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Figure 2. Kaplan-Meier survival curves of infected patients
and noninfected patients after orthotopic liver transplantation.
308 T.-C. Chen et al.transplantation. The incidence of invasive fungal infections
in our patients (8.8%) was similar to that reported in other
studies (2e23.8%),3,5,7,9 and unlike the study,4 that has high
fungal infection rate (42%), which may be because of higher
rates of steroid and antimicrobial use before trans-
plantation than other studies. In comparison with other
reports,3e7,22e24 our patients had similar time courses in
acquiring invasive fungal infections (first 2 months post-
transplantation for Candida; first 3 months for Aspergillus;
after 6 months posttransplantation for Cryptococcosis).
CMV infection/disease has been reported to occur in
25e80% of liver transplant recipients,25,26 but we only had
one patient with CMV infection. We believe that our low
CMV infection rate is an underestimation, because CMV
pp65 or DNA analysis was only performed in patients with
unexplained elevation of liver enzymes. Furthermore, the
time courses of HSV and varicella-zoster virus infections in
our patients were similar to those of previous studies,6,27
although our patients had a lower rate of HSV infection
(5.9%, 4/68). However, our HSV oral-labial reactivation rate
may also be an underestimate, because culturing for oral
lesions was not always performed at the proper times.
Rejection is another important risk factor for infectious
complications after liver transplantation.28 The incidence
of acute rejection, including confirmed (9/68, 13.2%) and
possible cases (7/68, 10.3%), was 23.5% (16/68), which was
similar to other studies.28e30 MTP pulse therapy plays
a major role in suppressing acute rejection, but it has been
reported to increase the risk of infection,10 similar to our
observations. Our overall mortality rate was 11.7% (8/68)
and the mortality rate of infected patients was 14% (4/29),
comparable to those reported previously.1e3 As described
previously,2,3 retransplantation (p < 0.001) and infection
(p < 0.001), especially invasive fungal infection, were the
main risk factors associated with mortality.
There were several limitations to our study. First, our
study was retrospective, so the clinical infectious signs and
symptoms might be underrecorded. Second, our sample
size (n Z 68) was somewhat small. Third, our study was
performed at a single hospital, so the results might not be
applicable to other health care facilities in Taiwan. Fourth,
culture was not all done when infection was suspected.In this study, episode was collected only when a positive
culture result was seen. This underestimated the true
bacterial infection episodes.
In conclusion, we found that bacterial infection is the
most common infectious disease after liver transplantation.
The operation-related complications, especially biliary
tract stricture, are important risk factors for bacterial
infection. Retransplantation and infections are associated
with significantly higher mortality rate in transplant recip-
ients. Our results suggest that the currently recommended
time for stent replacement (3 months) should be reeval-
uated for liver transplant patients.
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